Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of TAK-385 in Healthy Women
NCT02792062Phase 1Completed
- Sponsor
- Takeda
- Start
- Jul 2016
- Primary completion
- Aug 2016
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of relugolix in Uterine Fibroids (UF) and endometriosis (6 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 1, Area Under the Plasma Concentration-time Curve From Time 0 to Infinity at Day 1 and 2 more. Started Jul 2016; status: completed.
02
Drugs
relugolix
03
Conditions
Uterine Fibroids (UF)endometriosis
Beyond the preview
Go deeper on NCT02792062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792062.